Physician profile
Mark D Le
NPI 1033153002
$7,621.35
in general payments reported to CMS, 2019-2025
32 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $858 · 2021: $1,082 · 2022: $901 · 2023: $1,063 · 2024: $1,735 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,150 · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,150.45 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,894.98 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $1,114.91 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $859.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $423.28 | 2019-2023 | |
| Lilly USA, LLC | $372.17 | 2019-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $361.80 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $325.25 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $305.43 | 2019-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $190.12 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $171.02 | 2020-2024 | Livalo, Seglentis |
| Abbvie INC. | $165.18 | 2021-2025 | |
| Pfizer INC. | $161.77 | 2019-2025 | |
| Astellas Pharma US INC | $153.34 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $146.84 | 2021-2023 | |
| Si-Bone, INC. | $138.21 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $134.83 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.61 | 2023-2025 | |
| Esperion Therapeutics, INC. | $78.07 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $71.06 | 2020-2022 | |
| Abiomed | $53.22 | 2024 | Impella |
| Bigfoot Biomedical INC | $51.63 | 2022 | |
| Arbor Pharmaceuticals, INC. | $48.60 | 2020-2021 | |
| Tandem Diabetes Care, INC. | $47.80 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $46.30 | 2025 | Cequr Simplicity |
| Beta Bionics, INC. | $45.39 | 2024 | Ilet Bionic Pancreas |
| Exact Sciences Corporation | $36.74 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $29.12 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $29.06 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Boston Scientific Corporation | $18.46 | 2025 | Axonics |
| Genentech USA, INC. | $17.92 | 2019 | |
| Inari Medical, INC. | $16.92 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.58 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.